AIHTA - Publications - Search - Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Oncology Fact Sheet Nr. 102.

[thumbnail of Oncology Fact Sheet Nr.102.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
99kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 800-910 Breast
Language:English
Series Name:Oncology Fact Sheet Nr. 102
Deposited on:26 Jul 2022 14:54
Last Modified:26 Jul 2022 14:54

Repository Staff Only: item control page